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The Zn K-edge extended X-ray absorption fine structure (EXAFS) spectra, of 
the dapE-encoded N-succinyl-l,l-diaminopimelic acid desuccinylase (DapE) 
from Haemophilus influenzae have been recorded in the presence of one or 
two equivalents of Zn(II) (i.e. [Zn_(DapE)] and [ZnZn(DapE)]). The Fourier 
transforms of the Zn EXAFS are dominated by a peak at ca. 2.0 Å, which can 
be fit for both [Zn_(DapE)] and [ZnZn(DapE)], assuming ca. 5 (N,O) 
scatterers at 1.96 and 1.98 Å, respectively. A second-shell feature at ca. 3.34 
Å appears in the [ZnZn(DapE)] EXAFS spectrum but is significantly diminished 
in [Zn_(DapE)]. These data show that DapE contains a dinuclear Zn(II) active 
site. Since no X-ray crystallographic data are available for any DapE enzyme, 
these data provide the first glimpse at the active site of DapE enzymes. In 
addition, the EXAFS data for DapE incubated with two competitive inhibitors, 
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2-carboxyethylphosphonic acid and 5-mercaptopentanoic acid, are also 
presented.  
According to recent estimates from the United States Centers 
for Disease Control and Prevention (the CDC), more than 10 million 
people died worldwide from bacterial infections in 1995.1 Tuberculosis, 
for example, was the leading cause of death in adults by an infectious 
disease.2 The importance of developing new drugs to fight infectious 
disease, such as tuberculosis, is underscored by the emergence of 
several pathogenic bacterial strains that are resistant to all currently 
available antibiotics.3-6 To overcome bacterial resistance to antibiotics, 
new enzyme targets must be located and small-molecule inhibitors 
developed. The meso-diaminopimelate (mDAP)/lysine biosynthetic 
pathway offers several potential anti-bacterial targets that have yet to 
be explored.7-9 Since both products of this pathway, mDAP and lysine, 
are essential components of the peptidoglycan cell wall in Gram-
negative and some Gram-positive bacteria, inhibitors of enzymes 
within this pathway may provide a new class of antibiotics.5 The fact 
that there are no similar pathways in mammals suggests that 
inhibitors of enzymes in the mDAP/lysine pathway will provide 
selective toxicity against bacteria and will potentially have little or no 
effect on humans.  
 
One of the enzymes in this pathway,10 the dapE-encoded N-
succinyl-l,l-diaminopimelic acid desuccinylase (DapE), catalyzes the 
hydrolysis of N-succinyl-l,l-diaminopimelate to l,l-diaminopimelate and 
succinate.11 It has been shown that deletion of the gene encoding 
DapE is lethal to Helicobacter pylori and Mycobacterium 
smegmatis.12,13 Even in the presence of lysine-supplemented media, 
the DapE deletion cell line of H. pylori was unable to grow. Therefore, 
DapEs are essential for cell growth and proliferation. Since no 
structural data of any kind are available for DapE enzymes, we have 
recorded the Zn K-edge extended X-ray absorption fine structure 
(EXAFS) spectra of the DapE from H. influenzae in the presence of one 
or two equivalents of Zn(II) (i.e. [Zn_(DapE)] and [ZnZn(DapE)]) 
(Figure 1). For [ZnZn(DapE)] the EXAFS data report an average of 
both metal ion environments. The Fourier transforms of both 
[Zn_(DapE)] and [ZnZn(DapE)] are dominated by a peak at ca. 2.0 Å, 
that can be fit for both [Zn_(DapE)] and [ZnZn(DapE)] assuming 5 
(N,O) scatterers, at 1.96 and 1.98 Å, respectively (Fits 1,3; Table 1). A 
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second shell feature at ca. 3.3 Å appears in the [ZnZn(DapE)] EXAFS 
spectrum but is significantly diminished in [Zn_(DapE)]. Fits 
incorporating a Zn−Zn interaction at 3.34 Å for [ZnZn(DapE)] have 
reasonable Debye−Waller factors (Fit 4; Table 1) and resulted in a 
significant improvement in goodness-of-fit values (f ‘). Therefore, the 
second-shell FT feature observed at 3.34 Å is consistent with a 
dinuclear Zn(II) active site in DapE. Although fits for [Zn_(DapE)] that 
include a Zn−Zn interaction improve the f ‘ values slightly, the 
Debye−Waller factor value for this interaction is significantly higher 
than for the same interaction in [ZnZn(DapE)] (cf. Fits 2,4; Table 1).  
 
 
Figure 1 Zn K-edge X-ray absorption spectra for [Zn_(DapE)] (dashed) and 
[ZnZn(DapE)] (solid). (A) Zn edge spectra; (B) k3-weighted Zn EXAFS; (C) Fourier 
transforms over k = 2−13 Å-1, with S phase correction. 
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Figure 2 Zn K-edge X-ray absorption spectra of [ZnZn(DapE)] in the absence (black) 
and presence of CEPA (blue) or MSPA (red) and [ZnZn(APP)] in the presence of LPA 
(green). (A) Zn edge spectra; (B) k3-weighted Zn EXAFS; (C) Fourier transforms over 
k = 2−13 Å-1, with S phase correction. 
Table 1.  Curve-Fitting Results for Zn EXAFSa of DapE Enzymes 
sample filename (k range) Δk3χ fit shell Ras (Å) σas2 (Å2) ΔE0 (eV) f ‘ b  
[Zn_(DapE)]  1  Zn−O5  1.96  0.0062  −9.11  0.104  
ZDZ0A (2−13 Å-1)  2  Zn−O5  1.96  0.0062  −9.30  0.100  
Δk3χ = 10.23    Zn−Zn  3.30  0.0117      
[ZnZn(DapE)]  3  Zn−O5  1.98  0.0065  −9.01  0.111  
ZDZ0A (2−13 Å-1)  4  Zn−O5  1.98  0.0064  −9.41  0.093  
Δk3χ = 10.44    Zn−Zn  3.34  0.0051      
[ZnZn(AAP)]  5  Zn−O5  1.99  0.0084  −8.71  0.094  
ZAZZA (2−13 Å-1)  6  Zn−O5  1.99  0.0084  −9.12  0.089  
Δk3χ = 9.47    Zn−Zn  3.27  0.0099      
[ZnZn(DapE)]-CEPA  7  Zn−O5  1.99  0.0069  −8.00  0.096  
ZDZ0A (2−13 Å-1)  8  Zn−O5  1.99  0.0085  −8.42  0.088  
Δk3χ = 9.89    Zn−Zn  3.34  0.0083      
[ZnZn(AAP)]-LPA  9  Zn−O5  1.99  0.0078  −8.22  0.108  
ZAZPA (2−13 Å-1)  10  Zn−O5  1.99  0.0077  −8.56  0.103  
Δk3χ = 9.91    Zn−Zn  3.30  0.0112      
  11  Zn−O5  1.99  0.0077  −8.49  0.103  
    Zn−Zn  3.80  0.0072      
[ZnZn(DapE)]-MSPA  12  Zn−O5  1.99  0.0079  −3.03  0.109  
ZDZTA (2−13 Å-1)  13  Zn−O5  1.99  0.0050  −6.24  0.097  
Δk3χ = 9.98    Zn−S  2.30  0.0089      
    Zn−Zn  3.64  0.0083      
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a  Shell is the chemical unit defined for the multiple scattering calculation, the number 
of scatterers per metal denoted by the subscript. Ras is the metal-scatterer distance. 
σas2 is a mean square deviation in Ras. ΔE0 is the shift in E0 for the theoretical 
scattering functions.b f ‘ is a normalized error (χ-squared):  f‘ = 
{∑i[k3(−)]2/N}1/2/[(k3χobs)max − (k3χobs)min]. 
Sequence alignments of several DapE genes with those of the 
crystallographically characterized aminopeptidase from Aeromonas 
proteolytica (AAP) and the carboxypeptidase G2 from Pseudomonas sp. 
strain RS-16 (CPG2), indicate that all of the amino acids that function 
as metal ligands in AAP and CPG2 are strictly conserved in DapEs.11,14-
16 The X-ray crystal structures of both CPG2 and AAP reveal a (μ-
aquo)(μ-carboxylato)dizinc(II) active site with one terminal 
carboxylate and histidine residue bound to each metal ion.15,16 Both 
Zn(II) ions in AAP and CPG2 reside in a distorted tetrahedral 
coordination geometry, with a Zn−Zn distance of 3.5 and 3.3 Å for 
AAP and CPG2, respectively.15,16 EXAFS data obtained for [ZnZn(AAP)] 
also contain a feature at 3.27 Å that can be modeled as a Zn−Zn 
vector (Fit 6; Table 1). Combination of these data indicates that DapE 
enzymes contain dinuclear Zn(II) active sites. In addition, on the basis 
of the first shell fits of [ZnZn(AAP)] and [ZnZn(DapE)], we propose 
that one carboxylate and one histidine residue resides at each Zn(II) 
site in DapE and that the two Zn(II) ions are bridged by one 
carboxylate residue and a water molecule.  
 
The first step in inhibitor design for DapE enzymes requires an 
understanding of how inhibitors bind to the active site. Therefore, we 
recorded the Zn K-edge EXAFS spectra of [ZnZn(DapE)] in the 
presence of the competitive inhibitors 2-carboxyethylphosphonic acid 
(CEPA) and 5-mercaptopentanoic acid (MSPA) (Figure 2). The EXAFS 
data for [ZnZn(DapE)]−CEPA indicate that the average coordination 
number of each Zn(II) ion remains five and the Zn−Zn distance 
remains 3.34 (Fits 7,8; Table 1). An increase in the M−M distance of 
[ZnZn(AAP)], from 3.5 to 3.9 Å, is observed upon the addition of the 
transition-state analogue inhibitor l-leucine-phosphonic acid (LPA) 
which contains a similar ligating group to CEPA.17 The X-ray crystal 
structure and EXAFS data for [ZnZn(AAP)]-LPA, reveal that the 
bridging water molecule is displaced by LPA resulting in an η-1,2-μ-
phosphonate bridge and an increase in the Zn−Zn distance of 0.4 Å 
(Fit 11; Table 1). The fact that the Zn−Zn distance does not change 
upon CEPA binding to [ZnZn(DapE)] suggests an η-1-μ-phosphonate 
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bridge exists, similar to the binding mode of LPA to the leucine 
aminopeptidase from bovine lens.17,18 On the other hand, MSPA 
binding to [ZnZn(DapE)] has a marked effect on the Zn K-edge, 
suggesting that the average electronic environment of the dinuclear 
Zn(II) site has changed significantly (Figure 2). The observed shift to 
lower energy in the absorption edge position is indicative of a net 
increase in electron density at the dinuclear Zn(II) site, consistent with 
a sulfur ligand. In addition, the EXAFS data for [ZnZn(DapE)]−MSPA 
reveal a new feature at 2.3 Å that is highly characteristic of a direct 
zinc−sulfur interaction (Fits 12,13; Table 1). Moreover, the M−M 
distance is lengthened from 3.34 to 3.64 Å. These data indicate that 
the thiol group of MSPA binds to one or more of the Zn(II) ions in the 
active site of DapE.  
 
In conclusion, DapEs are potential molecular targets for a new 
and novel class of antibiotics. The EXAFS data presented herein 
provide the first structural information for any DapE enzyme and also 
establish the binding modes of phosphonate- and thiolate-containing 
inhibitors. In addition, the structural data obtained for CEPA bound to 
[ZnZn(DapE)] provide the first glimpse at the transition state of the 
hydrolysis reaction catalyzed by DapE. Since most pharmaceuticals 
target the transition state of enzymatic reactions, the structural 
aspects of [ZnZn(DapE)]−CEPA are particularly important for the 
rational design of new potent inhibitors of DapE enzymes.  
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